

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application. Please cancel claims 103, 105, 121 and 123-127.

Listing of Claims:

Claims 1-94 (Cancelled).

95. (Previously Presented) A recombinant polypeptide comprising a pleiotrophin (PTN)-binding fragment of anaplastic lymphoma kinase (ALK), wherein the PTN-binding fragment consists of amino acid residues 368 to 447 of SEQ ID NO:2, and wherein said recombinant polypeptide does not comprise further regions of ALK.

96. (Previously Presented) The polypeptide of claim 95, wherein said polypeptide is soluble.

97-98. (Cancelled).

99. (Previously Presented) The polypeptide of claim 95 bound to PTN.

100. (Previously Presented) The polypeptide of claim 95 immobilized on a surface.

101. (Previously Presented) A composition comprising the polypeptide of claim 95, further comprising a pharmaceutically acceptable carrier.

102-103. (Cancelled).

104. (Previously Presented) The composition of claim 101, further comprising PTN.

105-118. (Cancelled).

119. (Previously Presented) The recombinant polypeptide of claim 95, further comprising an Fc domain.

120. (Previously Presented) A composition comprising the peptide of claim 119, further comprising a pharmaceutically acceptable carrier.

121. (Cancelled).

122. (Previously Presented) The composition of claim 120, further comprising PTN.

123-127. (Cancelled).